Press

Innovation, research, and the future: biotechnology sets the course for psoriasis treatment

29/10/2025

Healthcare · Access to innovation · Innovative drugs

• Biotechnology enables the development of more effective and personalized treatments for chronic inflammatory diseases such as psoriasis, improving the quality of life for millions of people.
• Inhibitec Anticuerpos, an AseBio member company, is researching a new therapeutic target called BAMBI, with promising results in both the skin and joint manifestations of the disease.
• Collaboration with patients and international foundations drives research that is closer, more human, and focused on the real needs of those living with psoriasis.

AseBio

Biotechnology emerges as Spain’s key tool against climate change: nearly 600 solutions developed to drive the green transition

24/10/2025

Climate change · Agrifood · Food & feed · Agriculture

• In the face of climate change, ecosystem degradation, and population growth, moving toward a sustainable economic model is urgent. The green transition stands as the essential roadmap, with biotechnology as the engine of change, according to Spain’s 2050 Strategy.
• At AseBio, our Sustainability Commission has prepared the report “Biotechnology Applied to the Green Transition,” which analyzes the solutions, areas of action, distribution, and challenges of our member companies to promote a more sustainable future.
• The report compiles 587 solutions from 66 companies and 20 organizations contributing to Spain’s green transition, organized into 27 activity areas across food innovation, bioprocesses, sustainable agriculture, and bioproducts.

AseBio

Biotechnology: a key ally in the fight against breast cancer

19/10/2025

Healthcare

• Biotechnological innovation is transforming treatments toward safer, more effective and personalized options.
• Nanotechnology-based therapies mark a new era in oncology treatment.
• According to the AECC, around 35,875 new cases were diagnosed in 2024, accounting for nearly 29% of all tumors detected in women.

AseBio

Biotechnology: A key ally in the challenge of feeding 10 billion people

16/10/2025

Climate change · Agrifood · Food & feed · Agriculture

• Biotechnology drives solutions to optimize the use of natural resources, reduce emissions, and advance toward a circular economy.
• The development of alternative proteins — plant-based, microbial, or cultivated — stands out as one of the most promising pathways to ensure future food security.
• Collaboration among technology centers, industry, and public administrations will be essential to accelerate the transition toward sustainable food systems.

AseBio

The union of synthetic biology, artificial intelligence, and automation drives new biofuels, proteins, and gene therapies

09/10/2025

BioSpain

• Artificial intelligence enables the analysis of millions of biological data points to identify optimal solutions, while automation facilitates the transfer of results from the lab to industry.
• Cultivated meat and plant-based proteins are revolutionizing the meat industry with nutrient-rich, safer foods: they reduce risks associated with zoonotic pathogens, antibiotic residues, and microbiological contaminants.
• Gas fermentation and the use of photosynthetic organisms make it possible to convert CO₂ into high-value bioproducts such as biofuels, bioplastics, proteins, and biomass for food or fertilizers.

AseBio

BIOSPAIN 2025 closes with record attendance and passes the baton to Bilbao as 2026 host city

09/10/2025

BioSpain

• The edition closes with more than 2,400 attendees from over 1,000 organizations across 34 countries.
• BIOSPAIN 2025 brought together 140 investors representing 76 national and international investment entities, and facilitated more than 4,500 meetings.
• BIOSPAIN consolidates itself as a strategic platform to strengthen public-private cooperation, boost the internationalization of biotech companies, and foster frontier research.
  
   

AseBio

Advanced therapies: a strategic pillar for European autonomy in biotechnology and health

08/10/2025

BioSpain

• Early Health Technology Assessment (HTA) prevents investments in developments that will not deliver real value, while allowing patients faster access to truly innovative treatments.
• The upcoming Biotech Act and the European Pharmaceutical Strategy are crucial for the development of advanced therapies in Europe, as they aim to create a more agile and predictable regulatory framework that facilitates innovation, clinical research, and industrial production of these treatments.
• Experts point out that effective implementation of artificial intelligence in hospital settings requires proper data infrastructure, interoperability strategies, and clear regulatory frameworks to accelerate clinical impact.
  
   

AseBio

Investing in Biotechnology: A Commitment to Excellence and the Real Impact of Innovation on Patients

08/10/2025

BioSpain

• Experts advocate for the convergence of biotechnology, engineering, and digitalization as a driving force for industrial transformation, while emphasizing the need for multidisciplinary talent and collaborative frameworks to accelerate innovation.
• The Spanish biotech ecosystem, despite its progress in investment, R&D, business creation, and international visibility, still needs to strengthen public-private collaborations and take greater advantage of European funding instruments.
• Venture capital funds are a key driver of growth for biotech start-ups, which must balance their high capital needs with the inherent uncertainty of the sector.
   

AseBio

BIOSPAIN 2025 kicks off in Barcelona: the leading national meeting point for biotechnology and one of Europe’s top references

07/10/2025

BioSpain

• From October 7–9, the Fira de Barcelona will host the 12th edition of BIOSPAIN, organized by AseBio and Biocat, in collaboration with the Government of Catalonia and the Barcelona City Council.
• The opening ceremony featured Rocío Arroyo, President of AseBio; Juan Cruz Cigudosa, Secretary of State for Science, Innovation and Universities; Antoni Plasència i Taradach, Director General for Research and Innovation at the Department of Health of the Government of Catalonia; and Jordi Valls Riera, Deputy Mayor for Economy, Housing, Treasury and Tourism of the Barcelona City Council.
• One of this year’s major novelties: BIOSPAIN will now become an annual event instead of a biennial one. The host city for BIOSPAIN 2026 will be announced on October 9 in a special ceremony.
   

AseBio